Actively Recruiting
PET Imaging of MMP Activation in AAA: Clinical Component
Led by Washington University School of Medicine · Updated on 2026-03-18
28
Participants Needed
1
Research Sites
73 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A first-in-human evaluation of \[64Cu\]-RYM2 with PET/CT will be performed to: a) assess its safety, biodistribution, and radiation dosimetry in normal volunteers (WU) and; b) in AAA patients undergoing surgery (WU and Yale), evaluate radiotracer pharmacodynamics and correlate PET imaging characteristics (WU) with ex vivo tissue measurements (Yale).
CONDITIONS
Official Title
PET Imaging of MMP Activation in AAA: Clinical Component
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy volunteers with no history of claustrophobia or other conditions preventing completion of imaging sessions
- Able to understand and follow study instructions
- Able to lie still and supine in PET/CT scanner for about 1 hour and follow breathing instructions
- No illicit or inhaled drug use in the past year
- No known cardiac, lung, liver, kidney disease, or diabetes
- Body mass index (BMI) of 40 or less
- Patients with AAA aged 40 to 80 years scheduled for elective or semi-elective surgical repair
- Willing and able to provide informed consent
- Medically managed hypertension and hyperlipidemia
- No history of claustrophobia or other conditions preventing imaging completion
- Able to understand and follow study instructions
- AAA size meets surgical repair criteria or rapidly expanding as per vascular surgery guidelines
You will not qualify if you...
- Unable to provide informed consent
- Pregnant or breastfeeding
- Chronic kidney disease with GFR under 30 mL/min/1.73 m2
- Unstable clinical condition preventing study participation
- Unable to lie still for 60 minutes in supine position during PET imaging due to pain or other issues
- Current use of recreational drugs
- Body weight over 300 pounds (PET table limit)
- Participation in another investigational drug or radiotracer study within the past year that would interfere with results
- Documented allergy to iodinated contrast or shellfish
- Other serious medical conditions such as recent coronary disease, cancer under treatment, or autoimmune/inflammatory diseases
- Non-AAA volunteers with significantly progressed aortoiliac occlusive disease as assessed by a vascular surgeon
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Washington University School of Medicine
St Louis, Missouri, United States, 63110
Actively Recruiting
Research Team
K
Kitty Harrison, RN, BSN
CONTACT
R
Robert Gropler, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here